cancer vaccine

Investors sold despite positive melanoma vaccine trial results, pointing to lingering doubts about Moderna's ability to execute beyond COVID and generate sustainable returns.

Intismeran, combined with Keytruda, reduced melanoma recurrence—the first neoantigen vaccine to clear a late-stage randomized trial.